LNCaP Atlas: Gene expression associated with in vivo progression to castration-recurrent prostate cancer

BMC Medical Genomics

Volumn 3, Issue , 2010, Pages

  Romanuik, Tammy L ^a   Wang, Gang ^a   Morozova, Olena ^a   Delaney, Allen ^a   Marra, Marco A ^a   Sadar, Marianne D ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

17BETA HYDROXYSTEROID DEHYDROGENASE 4; 24 DEHYDROCHOLESTEROL REDUCTASE; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; ANDROGEN RECEPTOR; CALCIUM BINDING PROTEIN; CELL PROTEIN; CUE DOMAIN CONTAINING 2; CYCLIN H; DEHYDROGENASE REDUCTASE SDR FAMILY MEMBER 7; ELONGATION OF LONG CHAIN FATTY ACID FAMILY MEMBER 5; FILAMIN A; GUANINE NUCLEOTIDE BINDING PROTEIN BETA SUBUNIT; NEUROENDOCRINE SPECIFIC PROTEIN; NEURONAL ENOLASE 2; NK3 HOMEOBOX 1; OPIOID RECEPTOR KAPPA 1; PROGESTERONE RECEPTOR; PROTEASOME MACROPAIN SUBUNIT ALPHA TYPE 7; PROTEIN GAS5; PROTEIN MT ND3; PROTEIN PCGEM1; PROTEIN STEAP1; PROTEIN TMEM30A; REGULATOR PROTEIN; S100 CALCIUM BINDING PROTEIN A10; STEROID; TRANSIENT RECEPTOR POTENTIAL CHANNEL M8; UNCLASSIFIED DRUG; RNA;

ANIMAL CELL; ARTICLE; CANCER GROWTH; CASTRATION; CELL STRAIN LNCAP; CELL SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE LIBRARY; GENETIC CODE; GENETIC TRANSCRIPTION; GLEASON SCORE; IN VIVO STUDY; MALE; METASTASIS; MOUSE; NEUROENDOCRINE SYSTEM; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN SECRETION; RECURRENT CANCER; STEROID METABOLISM; STEROIDOGENESIS; UNINDEXED SEQUENCE; UPREGULATION; ANIMAL; BIOSYNTHESIS; CLUSTER ANALYSIS; DISEASE COURSE; GENETIC DATABASE; GENETICS; HUMAN; METABOLISM; PRINCIPAL COMPONENT ANALYSIS; PROSTATE TUMOR;

ANIMALS; CLUSTER ANALYSIS; DATABASES, GENETIC; DISEASE PROGRESSION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMANS; MALE; MICE; PRINCIPAL COMPONENT ANALYSIS; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; RNA; STEROIDS;

EID: 77956896027     PISSN: None     EISSN: 17558794     Source Type: Journal    
DOI: 10.1186/1755-8794-3-43     Document Type: Article

References (147)

1. The development of androgen-independent prostate cancer. BJ Feldman D Feldman, Nat Rev Cancer 2001 1 1 34 45 10.1038/35094009 11900250
2. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. HI Scher CL Sawyers, J Clin Oncol 2005 23 32 8253 8261 10.1200/JCO.2005.03.4777 16278481
3. Mechanisms of the development of androgen independence in prostate cancer. A So M Gleave A Hurtado-Col C Nelson, World J Urol 2005 23 1 1 9 10.1007/s00345-004-0473-1 15770516
4. Mechanisms of prostate cancer progression to androgen independence. MJ McPhaul, Best Pract Res Clin Endocrinol Metab 2008 22 2 373 388 10.1016/j.beem.2008.02.006 18471793
5. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. T Visakorpi E Hyytinen P Koivisto M Tanner R Keinanen C Palmberg A Palotie T Tammela J Isola OP Kallioniemi, Nat Genet 1995 9 4 401 406 10.1038/ng0495-401 7795646
6. Androgen receptor gene amplification and protein expression in recurrent prostate cancer. OH Ford CW Gregory D Kim AB Smitherman JL Mohler, J Urol 2003 170 5 1817 1821 10.1097/01.ju.0000091873.09677.f4 14532783 (Pubitemid 37254935)
7. A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. CW Gregory B He RT Johnson OH Ford JL Mohler FS French EM Wilson, Cancer Res 2001 61 11 4315 4319 11389051
8. Androgen receptor coregulators and their involvement in the development and progression of prostate cancer. R Chmelar G Buchanan EF Need W Tilley NM Greenberg, Int J Cancer 2007 120 4 719 733 10.1002/ijc.22365 17163421
9. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. J Holzbeierlein P Lal E LaTulippe A Smith J Satagopan L Zhang C Ryan S Smith H Scher P Scardino, et al. Am J Pathol 2004 164 1 217 227 14695335
10. Intracrine androgen metabolism in prostate cancer progression: mechanisms of castration resistance and therapeutic implications. EA Mostaghel PS Nelson, Best Pract Res Clin Endocrinol Metab 2008 22 2 243 258 10.1016/j.beem.2008.01. 003 18471783
11. Adrenal androgens and intracrinology. F Labrie, Semin Reprod Med 2004 22 4 299 309 10.1055/s-2004-861547 15635498
12. The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens. J Veldscholte CA Berrevoets C Ris-Stalpers GG Kuiper G Jenster J Trapman AO Brinkmann E Mulder, J Steroid Biochem Mol Biol 1992 41 3-8 665 669 10.1016/0960-0760(92)90401-4 1562539
13. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Z Culig A Hobisch MV Cronauer C Radmayr J Trapman A Hittmair G Bartsch H Klocker, Cancer Res 1994 54 20 5474 5478 7522959
14. Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor. A Hobisch IE Eder T Putz W Horninger G Bartsch H Klocker Z Culig, Cancer Res 1998 58 20 4640 4645 9788616
15. Activation of the human androgen receptor through a protein kinase A signaling pathway. LV Nazareth NL Weigel, J Biol Chem 1996 271 33 19900 19907 10.1074/jbc.271.33.19900 8702703
16. The promoter of the prostate-specific antigen gene contains a functional androgen responsive element. PH Riegman RJ Vlietstra JA van der Korput AO Brinkmann J Trapman, Mol Endocrinol 1991 5 12 1921 1930 10.1210/mend-5-12-1921 1724287
17. Neuroendocrine-like prostate cancer cells: neuroendocrine transdifferentiation of prostate adenocarcinoma cells. TC Yuan S Veeramani MF Lin, Endocr Relat Cancer 2007 14 3 531 547 10.1677/ERC-07-0061 17914087
18. The biology of hormone refractory prostate cancer. Why does it develop? JT Isaacs, Urol Clin North Am 1999 26 2 263 273 10.1016/S0094-0143(05)70066-5 10361549
19. Serial analysis of gene expression. VE Velculescu L Zhang B Vogelstein KW Kinzler, Science 1995 270 5235 484 487 10.1126/science.270.5235.484 7570003
20. Using the transcriptome to annotate the genome. S Saha AB Sparks C Rago V Akmaev CJ Wang B Vogelstein KW Kinzler VE Velculescu, Nat Biotechnol 2002 20 5 508 512 10.1038/nbt0502-508 11981567
21. Characterization of a new in vivo hollow fiber model for the study of progression of prostate cancer to androgen independence. MD Sadar VA Akopian E Beraldi, Mol Cancer Ther 2002 1 8 629 637 12479223
22. Identification of genes targeted by the androgen and PKA signaling pathways in prostate cancer cells. G Wang SJ Jones MA Marra MD Sadar, Oncogene 2006 25 55 7311 7323 10.1038/sj.onc.1209715 16751804
23. Crosstalk between the androgen receptor and beta-catenin in castrate-resistant prostate cancer. G Wang J Wang MD Sadar, Cancer Res 2008 68 23 9918 9927 10.1158/0008-5472.CAN-08-1718 19047173
24. A mouse atlas of gene expression: large-scale digital gene-expression profiles from precisely defined developing C57BL/6J mouse tissues and cells. AS Siddiqui J Khattra AD Delaney Y Zhao C Astell J Asano R Babakaiff S Barber J Beland S Bohacec, et al. Proc Natl Acad Sci USA 2005 102 51 18485 18490 10.1073/pnas.0509455102 16352711
25. Gene Expression Omnibus. http://www.ncbi.nlm.nih.gov/geo/
26. DiscoverySpace. http://www.bcgsc.ca/bioinfo/software/discoveryspace/
27. Construction of phylogenetic trees. WM Fitch E Margoliash, Science 1967 155 760 279 284 10.1126/science.155.3760.279 5334057
28. Numerical methods for inferring evolutionary trees. J Felsenstein, Q Rev Biol 1982 57 379 404 10.1086/412935
29. TreeView: an application to display phylogenetic trees on personal computers. RD Page, Comput Appl Biosci 1996 12 4 357 358 8902363
30. Clustering analysis of SAGE data using a Poisson approach. L Cai H Huang S Blackshaw JS Liu C Cepko WH Wong, Genome Biol 2004 5 7 51 10.1186/gb-2004-5-7- r51 15239836
31. Genomic analysis of mouse retinal development. S Blackshaw S Harpavat J Trimarchi L Cai H Huang WP Kuo G Weber K Lee RE Fraioli SH Cho, et al. PLoS Biol 2004 2 9 247 10.1371/journal.pbio.0020247 15226823
32. NCBI reference sequences (RefSeq): a curated nonredundant sequence database of genomes, transcripts and proteins. KD Pruitt T Tatusova DR Maglott, Nucleic Acids Res 2007 35 Database 61 65 10.1093/nar/gkl842 17130148
33. DiscoverySpace: an interactive data analysis application. N Robertson M Oveisi-Fordorei SD Zuyderduyn RJ Varhol C Fjell M Marra S Jones A Siddiqui, Genome Biol 2007 8 1 6 10.1186/gb-2007-8-1-r6 17210078
34. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. M Ashburner CA Ball JA Blake D Botstein H Butler JM Cherry AP Davis K Dolinski SS Dwight JT Eppig, et al. Nat Genet 2000 25 1 25 29 10.1038/75556 10802651
35. Identifying biological themes within lists of genes with EASE. DA Hosack G Dennis Jr BT Sherman HC Lane RA Lempicki, Genome Biol 2003 4 10 70 10.1186/gb-2003-4-10-r70 14519205
36. The significance of digital gene expression profiles. S Audic JM Claverie, Genome Res 1997 7 10 986 995 9331369
37. KEGG for linking genomes to life and the environment. M Kanehisa M Araki S Goto M Hattori M Hirakawa M Itoh T Katayama S Kawashima S Okuda T Tokimatsu, et al. Nucleic Acids Res 2008 36 Database 480 484 18077471
38. The SWISS-PROT protein sequence database and its supplement TrEMBL in 2000. A Bairoch R Apweiler, Nucleic Acids Res 2000 28 1 45 48 10.1093/nar/28.1.45 10592178
39. FatiGO +: a functional profiling tool for genomic data. Integration of functional annotation, regulatory motifs and interaction data with microarray experiments. F Al-Shahrour P Minguez J Tarraga I Medina E Alloza D Montaner J Dopazo, Nucleic Acids Res 2007 35 Web Server 91 96 10.1093/nar/gkm260 17478504
40. Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences. RL Strausberg EA Feingold LH Grouse JG Derge RD Klausner FS Collins L Wagner CM Shenmen GD Schuler SF Altschul, et al. Proc Natl Acad Sci USA 2002 99 26 16899 16903 10.1073/pnas.242603899 12477932
41. Ensembl 2007. TJ Hubbard BL Aken K Beal B Ballester M Caccamo Y Chen L Clarke G Coates F Cunningham T Cutts, et al. Nucleic Acids Res 2007 35 Database 610 617 10.1093/nar/gkl996 17148474
42. Defining aggressive prostate cancer using a 12-gene model. TA Bismar F Demichelis A Riva R Kim S Varambally L He J Kutok JC Aster J Tang R Kuefer, et al. Neoplasia 2006 8 1 59 68 10.1593/neo.05664 16533427
43. Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. RB Shah R Mehra AM Chinnaiyan R Shen D Ghosh M Zhou GR Macvicar S Varambally J Harwood TA Bismar, et al. Cancer Res 2004 64 24 9209 9216 10.1158/0008-5472.CAN-04-2442 15604294
44. Global analysis of differentially expressed genes in androgen-independent prostate cancer. Q Wei M Li X Fu R Tang Y Na M Jiang Y Li, Prostate Cancer Prostatic Dis 2007 10 2 167 174 10.1038/sj.pcan.4500933 17199135
45. Clinical and biomarker correlates of androgenindependent, locally aggressive prostate cancer with limited metastatic potential. VJ Assikis KA Do S Wen X Wang JH Cho-Vega S Brisbay R Lopez CJ Logothetis P Troncoso CN Papandreou, et al. Clin Cancer Res 2004 10 20 6770 6778 10.1158/1078-0432.CCR- 04-0275 15501953
46. Increased expression of genes converting adrenal androgens to testosterone in androgenindependent prostate cancer. M Stanbrough GJ Bubley K Ross TR Golub MA Rubin TM Penning PG Febbo SP Balk, Cancer Res 2006 66 5 2815 2825 10.1158/0008-5472.CAN-05-4000 16510604
47. Molecular alterations in primary prostate cancer after androgen ablation therapy. CJ Best JW Gillespie Y Yi GV Chandramouli MA Perlmutter Y Gathright HS Erickson L Georgevich MA Tangrea PH Duray, et al. Clin Cancer Res 2005 11 19 Pt 1 6823 6834 10.1158/1078-0432.CCR-05-0585 16203770
48. Molecular features of hormone-refractory prostate cancer cells by genomewide gene expression profiles. K Tamura M Furihata T Tsunoda S Ashida R Takata W Obara H Yoshioka Y Daigo Y Nasu H Kumon, et al. Cancer Res 2007 67 11 5117 5125 10.1158/0008-5472.CAN-06-4040 17545589
49. Gene expression profiles of prostate cancer reveal involvement of multiple molecular pathways in the metastatic process. UR Chandran C Ma R Dhir M Bisceglia M Lyons-Weiler W Liang G Michalopoulos M Becich FA Monzon, BMC Cancer 2007 7 64 10.1186/1471-2407-7-64 17430594
50. Expression patterns of potential therapeutic targets in prostate cancer. T Zellweger C Ninck M Bloch M Mirlacher PA Koivisto HJ Helin MJ Mihatsch TC Gasser L Bubendorf, Int J Cancer 2005 113 4 619 628 10.1002/ijc.20615 15472903
51. Differential expression of 37 selected genes in hormone-refractory prostate cancer using quantitative taqman real-time RT-PCR. G Fromont L Chene M Vidaud G Vallancien P Mangin G Fournier P Validire A Latil O Cussenot, Int J Cancer 2005 114 2 174 181 10.1002/ijc.20704 15543616
52. Expression signatures that correlated with Gleason score and relapse in prostate cancer. M Bibikova E Chudin A Arsanjani L Zhou EW Garcia J Modder M Kostelec D Barker T Downs JB Fan, et al. Genomics 2007 89 6 666 672 10.1016/j.ygeno.2007.02.005 17459658
53. Molecular markers to identify patients at risk for recurrence after primary treatment for prostate cancer. C Kumar-Sinha AM Chinnaiyan, Urology 2003 62 Suppl 1 19 35 10.1016/j.urology.2003.10.007 14747039
54. Integration of gene expression profiling and clinical variables to predict prostate carcinoma recurrence after radical prostatectomy. AJ Stephenson A Smith MW Kattan J Satagopan VE Reuter PT Scardino WL Gerald, Cancer 2005 104 2 290 298 10.1002/cncr.21157 15948174
55. Survival analysis of genome-wide gene expression profiles of prostate cancers identifies new prognostic targets of disease relapse. SM Henshall DE Afar J Hiller LG Horvath DI Quinn KK Rasiah K Gish D Willhite JG Kench M Gardiner-Garden, et al. Cancer Res 2003 63 14 4196 4203 12874026
56. Gene expression profiling predicts clinical outcome of prostate cancer. GV Glinsky AB Glinskii AJ Stephenson RM Hoffman WL Gerald, J Clin Invest 2004 113 6 913 923 15067324
57. Use of expression analysis to predict outcome after radical prostatectomy. PG Febbo WR Sellers, J Urol 2003 170 6 Pt 2 11 19 discussion S19-20 10.1097/01.ju.0000095567.03807.a1 14610405
58. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. J Lapointe C Li JP Higgins M van de Rijn E Bair K Montgomery M Ferrari L Egevad W Rayford U Bergerheim, et al. Proc Natl Acad Sci USA 2004 101 3 811 816 10.1073/pnas.0304146101 14711987
59. FGFR1 and WT1 are markers of human prostate cancer progression. E Devilard F Bladou O Ramuz G Karsenty JP Dales G Gravis C Nguyen F Bertucci L Xerri D Birnbaum, BMC Cancer 2006 6 272 10.1186/1471-2407-6-272 17137506
60. Novel expressed sequences identified in a model of androgen independent prostate cancer. SN Quayle H Hare AD Delaney M Hirst D Hwang JE Schein SJ Jones MA Marra MD Sadar, BMC Genomics 2007 8 32 10.1186/1471-2164-8-32 17257419
61. Dysregulated expression of androgen-responsive and nonresponsive genes in the androgen-independent prostate cancer xenograft model CWR22-R1. LC Amler DB Agus C LeDuc ML Sapinoso WD Fox S Kern D Lee V Wang M Leysens B Higgins, et al. Cancer Res 2000 60 21 6134 6141 11085537
62. Gene expression in the LNCaP human prostate cancer progression model: progression associated expression in vitro corresponds to expression changes associated with prostate cancer progression in vivo. Q Chen JT Watson SR Marengo KS Decker I Coleman PS Nelson RA Sikes, Cancer Lett 2006 244 2 274 288 10.1016/j.canlet.2005.12.027 16500022
63. Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model. SD Morgenbesser RP McLaren B Richards M Zhang VR Akmaev SF Winter ND Mineva PJ Kaplan-Lefko BA Foster BP Cook, et al. Prostate 2007 67 1 83 106 10.1002/pros.20505 17013881
64. High molecular mass proteome of androgen-independent prostate cancer. H Kuruma S Egawa M Oh-Ishi Y Kodera M Satoh W Chen H Okusa K Matsumoto T Maeda S Baba, Proteomics 2005 5 4 1097 1112 10.1002/pmic.200401115 15712236
65. Identification of androgen-responsive genes that are alternatively regulated in androgen-dependent and androgen-independent rat prostate tumors. R Pfundt F Smit C Jansen T Aalders H Straatman W van der Vliet J Isaacs AG van Kessel J Schalken, Genes Chromosomes Cancer 2005 43 3 273 283 10.1002/gcc.20184 15834941
66. Hormone therapy failure in human prostate cancer: analysis by complementary DNA and tissue microarrays. L Bubendorf M Kolmer J Kononen P Koivisto S Mousses Y Chen E Mahlamaki P Schraml H Moch N Willi, et al. J Natl Cancer Inst 1999 91 20 1758 1764 10.1093/jnci/91.20.1758 10528027
67. Failure of hormone therapy in prostate cancer involves systematic restoration of androgen responsive genes and activation of rapamycin sensitive signaling. S Mousses U Wagner Y Chen JW Kim L Bubendorf M Bittner T Pretlow AG Elkahloun JB Trepel OP Kallioniemi, Oncogene 2001 20 46 6718 6723 10.1038/sj.onc.1204889 11709706
68. Androgen receptor expression in androgen-independent prostate cancer is associated with increased expression of androgen-regulated genes. CW Gregory KG Hamil D Kim SH Hall TG Pretlow JL Mohler FS French, Cancer Res 1998 58 24 5718 5724 9865729
69. Identification of differentially expressed genes associated with androgen-independent growth of prostate cancer. JL Mohler TL Morris OH Ford RF Alvey C Sakamoto CW Gregory, Prostate 2002 51 4 247 255 10.1002/pros.10086 11987153
70. Identification of novel androgen-responsive genes by sequencing of LongSAGE libraries. T Romanuik G Wang RA Holt SJM Jones MA Marra MD Sadar, BMC Genomics 2009 10 476 19832994
71. The program of androgen-responsive genes in neoplastic prostate epithelium. PS Nelson N Clegg H Arnold C Ferguson M Bonham J White L Hood B Lin, Proc Natl Acad Sci USA 2002 99 18 11890 11895 10.1073/pnas.182376299 12185249
72. Expression profiling of androgen-dependent and - independent LNCaP cells: EGF versus androgen signalling. JK Oosterhoff JA Grootegoed LJ Blok, Endocr Relat Cancer 2005 12 1 135 148 10.1677/erc.1.00897 15788645
73. Identification and validation of novel androgen-regulated genes in prostate cancer. AM Velasco KA Gillis Y Li EL Brown TM Sadler M Achilleos LM Greenberger P Frost W Bai Y Zhang, Endocrinology 2004 145 8 3913 3924 10.1210/en.2004-0311 15131019
74. Androgen-induced expression of endoplasmic reticulum (ER) stress response genes in prostate cancer cells. T Segawa ME Nau LL Xu RN Chilukuri M Makarem W Zhang G Petrovics IA Sesterhenn DG McLeod JW Moul, et al. Oncogene 2002 21 57 8749 8758 10.1038/sj.onc.1205992 12483528
75. Quantitative expression profile of androgen-regulated genes in prostate cancer cells and identification of prostate-specific genes. LL Xu YP Su R Labiche T Segawa N Shanmugam DG McLeod JW Moul S Srivastava, Int J Cancer 2001 92 3 322 328 10.1002/ijc.1196 11291065
76. Digital expression profiles of the prostate androgen-response program. N Clegg B Eroglu C Ferguson H Arnold A Moorman PS Nelson, J Steroid Biochem Mol Biol 2002 80 1 13 23 10.1016/S0960-0760(01)00167-4 11867260
77. Differentially expressed genes in the prostate cancer cell line LNCaP after exposure to androgen and anti-androgen. CM Coutinho-Camillo S Salaorni AS Sarkis MA Nagai, Cancer Genet Cytogenet 2006 166 2 130 138 10.1016/j. cancergencyto.2005.09.012 16631469
78. Transcriptional programs activated by exposure of human prostate cancer cells to androgen. SE DePrimo M Diehn JB Nelson RE Reiter J Matese M Fero R Tibshirani PO Brown JD Brooks, Genome Biol 2002 3 7 ESEARCH0032 10.1186/gb-2002-3-7-research0032 12184806
79. Androgen mediated regulation and functional implications of fkbp51 expression in prostate cancer. PG Febbo M Lowenberg AR Thorner M Brown M Loda TR Golub, J Urol 2005 173 5 1772 1777 10.1097/01.ju.0000155845.44729.ba 15821585
80. Quantitative profiling of LNCaP prostate cancer cells using isotopecoded affinity tags and mass spectrometry. KL Meehan MD Sadar, Proteomics 2004 4 4 1116 1134 10.1002/pmic.200300649 15048993
81. Identification of androgen-regulated genes in the prostate cancer cell line LNCaP by serial analysis of gene expression and proteomic analysis. A Waghray F Feroze MS Schober F Yao C Wood E Puravs M Krause S Hanash YQ Chen, Proteomics 2001 1 10 1327 1338 10.1002/1615-9861(200110)1:10<1327::AID- PROT1327>3.0.CO;2-B 11721644
82. Novel biomarkers for prostate cancer including noncoding transcripts. TL Romanuik T Ueda N Le S Haile TM Yong T Thomson RL Vessella MD Sadar, Am J Pathol 2009 175 6 2264 2276 10.2353/ajpath.2009.080868 19893039
83. PCGEM1, a prostate-specific gene, is overexpressed in prostate cancer. V Srikantan Z Zou G Petrovics L Xu M Augustus L Davis JR Livezey T Connell IA Sesterhenn K Yoshino, et al. Proc Natl Acad Sci USA 2000 97 22 12216 12221 10.1073/pnas.97.22.12216 11050243
84. STEAP: a prostate-specific cell-surface antigen highly expressed in human prostate tumors. RS Hubert I Vivanco E Chen S Rastegar K Leong SC Mitchell R Madraswala Y Zhou J Kuo AB Raitano, et al. Proc Natl Acad Sci USA 1999 96 25 14523 14528 10.1073/pnas.96.25.14523 10588738
85. PrLZ, a novel prostate-specific and androgen-responsive gene of the TPD52 family, amplified in chromosome 8q21.1 and overexpressed in human prostate cancer. R Wang J Xu O Saramaki T Visakorpi WM Sutherland J Zhou B Sen SD Lim N Mabjeesh M Amin, et al. Cancer Res 2004 64 5 1589 1594 10.1158/0008-5472.CAN-03- 3331 14996714
86. Identification of differentially expressed genes by serial analysis of gene expression in human prostate cancer. A Waghray M Schober F Feroze F Yao J Virgin YQ Chen, Cancer Res 2001 61 10 4283 4286 11358857
87. Identification of differentially expressed genes in human prostate cancer using subtraction and microarray. J Xu JA Stolk X Zhang SJ Silva RL Houghton M Matsumura TS Vedvick KB Leslie R Badaro SG Reed, Cancer Res 2000 60 6 1677 1682 10749139
88. Gene expression correlates of clinical prostate cancer behavior. D Singh PG Febbo K Ross DG Jackson J Manola C Ladd P Tamayo AA Renshaw AV D'Amico JP Richie, et al. Cancer Cell 2002 1 2 203 209 10.1016/S1535-6108(02)00030-2 12086878
89. Human prostate cancer and benign prostatic hyperplasia: molecular dissection by gene expression profiling. J Luo DJ Duggan Y Chen J Sauvageot CM Ewing ML Bittner JM Trent WB Isaacs, Cancer Res 2001 61 12 4683 4688 11406537
90. Decrease and gain of gene expression are equally discriminatory markers for prostate carcinoma: a gene expression analysis on total and microdissected prostate tissue. T Ernst M Hergenhahn M Kenzelmann CD Cohen M Bonrouhi A Weninger R Klaren EF Grone M Wiesel C Gudemann, et al. Am J Pathol 2002 160 6 2169 2180 12057920
91. Profiling and verification of gene expression patterns in normal and malignant human prostate tissues by cDNA microarray analysis. H Chaib EK Cockrell MA Rubin JA Macoska, Neoplasia 2001 3 1 43 52 10.1038/sj.neo.7900126 11326315
92. Molecular features of the transition from prostatic intraepithelial neoplasia (PIN) to prostate cancer: genome-wide gene-expression profiles of prostate cancers and PINs. S Ashida H Nakagawa T Katagiri M Furihata M Iiizumi Y Anazawa T Tsunoda R Takata K Kasahara T Miki, et al. Cancer Res 2004 64 17 5963 5972 10.1158/0008-5472.CAN-04-0020 15342375
93. Meta-analysis of microarrays: interstudy validation of gene expression profiles reveals pathway dysregulation in prostate cancer. DR Rhodes TR Barrette MA Rubin D Ghosh AM Chinnaiyan, Cancer Res 2002 62 15 4427 4433 12154050
94. Gene expression profiling in clinically localized prostate cancer: a four-gene expression model predicts clinical behavior. A Latil I Bieche L Chene I Laurendeau P Berthon O Cussenot M Vidaud, Clin Cancer Res 2003 9 15 5477 5485 14654526
95. Two-dimensional transcriptome profiling: identification of messenger RNA isoform signatures in prostate cancer from archived paraffin-embedded cancer specimens. HR Li J Wang-Rodriguez TM Nair JM Yeakley YS Kwon M Bibikova C Zheng L Zhou K Zhang T Downs, et al. Cancer Res 2006 66 8 4079 4088 10.1158/0008-5472.CAN-05-4264 16618727
96. Molecular genetic profiling of Gleason grade 4/5 prostate cancers compared to benign prostatic hyperplasia. TA Stamey JA Warrington MC Caldwell Z Chen Z Fan M Mahadevappa JE McNeal R Nolley Z Zhang, J Urol 2001 166 6 2171 2177 10.1016/S0022-5347(05)65528-0 11696729
97. Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. S Varambally J Yu B Laxman DR Rhodes R Mehra SA Tomlins RB Shah U Chandran FA Monzon MJ Becich, et al. Cancer Cell 2005 8 5 393 406 10.1016/j.ccr.2005.10.001 16286247
98. Identification of differentially expressed genes in organ-confined prostate cancer by gene expression array. A Chetcuti S Margan S Mann P Russell D Handelsman J Rogers Q Dong, Prostate 2001 47 2 132 140 10.1002/pros.1056 11340636
99. Delineation of prognostic biomarkers in prostate cancer. SM Dhanasekaran TR Barrette D Ghosh R Shah S Varambally K Kurachi KJ Pienta MA Rubin AM Chinnaiyan, Nature 2001 412 6849 822 826 10.1038/35090585 11518967
100. Expression profiling reveals hepsin overexpression in prostate cancer. JA Magee T Araki S Patil T Ehrig L True PA Humphrey WJ Catalona MA Watson J Milbrandt, Cancer Res 2001 61 15 5692 5696 11479199
101. Identification of potential diagnostic markers of prostate cancer and prostatic intraepithelial neoplasia using cDNA microarray. JH Bull G Ellison A Patel G Muir M Walker M Underwood F Khan L Paskins, Br J Cancer 2001 84 11 1512 1519 10.1054/bjoc.2001.1816 11384102
102. Gene expression analysis of prostate cancers. JH Luo YP Yu K Cieply F Lin P Deflavia R Dhir S Finkelstein G Michalopoulos M Becich, Mol Carcinog 2002 33 1 25 35 10.1002/mc.10018 11807955
103. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. DF Gleason GT Mellinger, J Urol 1974 111 1 58 64 4813554
104. A molecular correlate to the Gleason grading system for prostate adenocarcinoma. L True I Coleman S Hawley CY Huang D Gifford R Coleman TM Beer E Gelmann M Datta E Mostaghel, et al. Proc Natl Acad Sci USA 2006 103 29 10991 10996 10.1073/pnas.0603678103 16829574
105. Comprehensive gene expression analysis of prostate cancer reveals distinct transcriptional programs associated with metastatic disease. E LaTulippe J Satagopan A Smith H Scher P Scardino V Reuter WL Gerald, Cancer Res 2002 62 15 4499 4506 12154061
106. A molecular signature of metastasis in primary solid tumors. S Ramaswamy KN Ross ES Lander TR Golub, Nat Genet 2003 33 1 49 54 10.1038/ng1060 12469122
107. From androgen receptor to the general transcription factor TFIIH. Identification of cdk activating kinase (CAK) as an androgen receptor NH(2)-terminal associated coactivator. DK Lee HO Duan C Chang, J Biol Chem 2000 275 13 9308 9313 10.1074/jbc.275.13.9308 10734072
108. Proteasome activity is required for androgen receptor transcriptional activity via regulation of androgen receptor nuclear translocation and interaction with coregulators in prostate cancer cells. HK Lin S Altuwaijri WJ Lin PY Kan LL Collins C Chang, J Biol Chem 2002 277 39 36570 36576 10.1074/jbc.M204751200 12119296
109. CUE domain containing 2 regulates degradation of progesterone receptor by ubiquitinproteasome. PJ Zhang J Zhao HY Li JH Man K He T Zhou X Pan AL Li WL Gong BF Jin, et al. Embo J 2007 26 7 1831 1842 10.1038/sj.emboj.7601602 17347654
110. Filamin-A fragment localizes to the nucleus to regulate androgen receptor and coactivator functions. CJ Loy KS Sim EL Yong, Proc Natl Acad Sci USA 2003 100 8 4562 4567 10.1073/pnas.0736237100 12682292
111. High-mobility group chromatin proteins 1 and 2 functionally interact with steroid hormone receptors to enhance their DNA binding in vitro and transcriptional activity in mammalian cells. V Boonyaratanakornkit V Melvin P Prendergast M Altmann L Ronfani ME Bianchi L Taraseviciene SK Nordeen EA Allegretto DP Edwards, Mol Cell Biol 1998 18 8 4471 4487 9671457
112. The androgen axis in recurrent prostate cancer. JL Mohler CW Gregory OH Ford D Kim CM Weaver P Petrusz EM Wilson FS French, Clin Cancer Res 2004 10 2 440 448 10.1158/1078-0432.CCR-1146-03 14760063
113. Mutations in the 3beta-hydroxysterol Delta24-reductase gene cause desmosterolosis, an autosomal recessive disorder of cholesterol biosynthesis. HR Waterham J Koster GJ Romeijn RC Hennekam P Vreken HC Andersson DR FitzPatrick RI Kelley RJ Wanders, Am J Hum Genet 2001 69 4 685 694 10.1086/323473 11519011
114. Short-chain dehydrogenases/reductases in retina. F Haeseleer K Palczewski, Methods Enzymol 2000 316 372 383 full-text 10800688
115. Gene expression profiles linked to the hormonal induction of male-effect pheromone synthesis in goats (Capra hircus). Y Momozawa Y Takeuchi M Kitago K Masuda Y Kakuma C Hashizume T Ichimaru K Mogi H Okamura T Yonezawa, et al. Biol Reprod 2007 77 1 102 107 10.1095/biolreprod.106.059113 17392497
116. Localization of the candidate genes ELOVL5 and SCD1 for 'male effect' pheromone synthesis in goats (Capra hircus). M Kitago Y Momozawa K Masuda Y Wakabayashi A Date-Ito K Hagino-Yamagishi T Kikusui Y Takeuchi Y Mori, J Reprod Dev 2007 53 6 1329 1333 10.1262/jrd.19060 17827874
117. Hydroxysteroid dehydrogenases and pre-receptor regulation of steroid hormone action. TM Penning, Hum Reprod Update 2003 9 3 193 205 10.1093/humupd/dmg022 12861966
118. Effects of mu, kappa, and delta opioid receptor agonists on the function of hypothalamic-pituitary-adrenal axis in monkeys. JE Pascoe KL Williams P Mukhopadhyay KC Rice JH Woods MC Ko, Psychoneuroendocrinology 2008 33 4 478 486 10.1016/j.psyneuen.2008.01.006 18325678
119. RNA interference of achaete-scute homolog 1 in mouse prostate neuroendocrine cells reveals its gene targets and DNA binding sites. Y Hu T Wang GD Stormo JI Gordon, Proc Natl Acad Sci USA 2004 101 15 5559 5564 10.1073/pnas.0306988101 15060276
120. Nuclear transport of parathyroid hormone (PTH)-related protein is dependent on microtubules. MH Lam RJ Thomas KL Loveland S Schilders M Gu TJ Martin MT Gillespie DA Jans, Mol Endocrinol 2002 16 2 390 401 10.1210/me.16.2.390 11818509
121. Inhibition of monoamine oxidase A promotes secretory differentiation in basal prostatic epithelial cells. H Zhao R Nolley Z Chen SW Reese DM Peehl, Differentiation 2008 76 7 820 830 10.1111/j.1432-0436.2007.00263.x 18248494
122. Neuroendocrine differentiation in prostatic carcinoma. PA Abrahamsson, Prostate 1999 39 2 135 148 10.1002/(SICI)1097-0045(19990501)39:2<135::AID- PROS9>3.0.CO;2-S 10221570
123. Alterations in 5-HT1B receptor function by p11 in depressionlike states. P Svenningsson K Chergui I Rachleff M Flajolet X Zhang M El Yacoubi JM Vaugeois GG Nomikos P Greengard, Science 2006 311 5757 77 80 10.1126/science.1117571 16400147
124. Transient receptor potential channel TRPM8 agonists stimulate calcium influx and neurotensin secretion in neuroendocrine tumor cells. S Mergler MZ Strowski S Kaiser T Plath Y Giesecke M Neumann H Hosokawa S Kobayashi J Langrehr P Neuhaus, et al. Neuroendocrinology 2007 85 2 81 92 10.1159/000101693 17426390
125. Growth arrest in human T-cells is controlled by the non-coding RNA growth-arrest-specific transcript 5 (GAS5). M Mourtada-Maarabouni VL Hedge L Kirkham F Farzaneh GT Williams, J Cell Sci 2008 121 Pt 7 939 946 10.1242/jcs.024646 18354083
126. RACK1, an insulin-like growth factor I (IGF-I) receptor-interacting protein, modulates IGF-I-dependent integrin signaling and promotes cell spreading and contact with extracellular matrix. U Hermanto CS Zong W Li LH Wang, Mol Cell Biol 2002 22 7 2345 2365 10.1128/MCB.22.7.2345-2365.2002 11884618
127. Nkx3.1 mutant mice recapitulate early stages of prostate carcinogenesis. MJ Kim R Bhatia-Gaur WA Banach-Petrosky N Desai Y Wang SW Hayward GR Cunha RD Cardiff MM Shen C Abate-Shen, Cancer Res 2002 62 11 2999 3004 12036903
128. Elevated expression of PCGEM1, a prostate-specific gene with cell growth-promoting function, is associated with high-risk prostate cancer patients. G Petrovics W Zhang M Makarem JP Street R Connelly L Sun IA Sesterhenn V Srikantan JW Moul S Srivastava, Oncogene 2004 23 2 605 611 10.1038/sj.onc.1207069 14724589
129. AKR1C2 and AKR1C3 mediated prostaglandin D(2) metabolism augments the PI3K/Akt proliferative signaling pathway in human prostate cancer cells. S Wang Q Yang KM Fung HK Lin, Mol Cell Endocrinol 2008 289 1-2 60 66 10.1016/j.mce.2008.04.004 18508192
130. Monoclonal antibodies to six-transmembrane epithelial antigen of the prostate-1 inhibit intercellular communication in vitro and growth of human tumor xenografts in vivo. PM Challita-Eid K Morrison S Etessami Z An KJ Morrison JJ Perez-Villar AB Raitano XC Jia JM Gudas SB Kanner, et al. Cancer Res 2007 67 12 5798 5805 10.1158/0008-5472.CAN-06-3849 17575147
131. Identification and characterization of CDC50A, CDC50B and CDC50C genes in silico. Y Katoh M Katoh, Oncol Rep 2004 12 4 939 943 15375526
132. In search of a function for the TIS21/PC3/BTG1/TOB family. S Matsuda J Rouault J Magaud C Berthet, FEBS Lett 2001 497 2-3 67 72 10.1016/S0014-5793(01) 02436-X 11377414
133. Characterization of FGFRL1, a novel fibroblast growth factor (FGF)
134. PCOTH, a novel gene overexpressed in prostate cancers, promotes prostate cancer cell growth through phosphorylation of oncoprotein TAF-Ibeta/SET. Y Anazawa H Nakagawa M Furihara S Ashida K Tamura H Yoshioka T Shuin T Fujioka T Katagiri Y Nakamura, Cancer Res 2005 65 11 4578 4586 10.1158/0008-5472.CAN-04- 4564 15930275
135. Glyoxalase I is involved in resistance of human leukemia cells to antitumor agent-induced apoptosis. H Sakamoto T Mashima A Kizaki S Dan Y Hashimoto M Naito T Tsuruo, Blood 2000 95 10 3214 3218 10807791
136. Interference of BAD (Bcl-xL/Bcl-2-associated death promoter)-induced apoptosis in mammalian cells by 14-3-3 isoforms and P11. SY Hsu A Kaipia L Zhu AJ Hsueh, Mol Endocrinol 1997 11 12 1858 1867 10.1210/me.11.12.1858 9369453
137. Evidence that TRPM8 is an androgen-dependent Ca2+ channel required for the survival of prostate cancer cells. L Zhang GJ Barritt, Cancer Res 2004 64 22 8365 8373 10.1158/0008-5472.CAN-04-2146 15548706
138. The phosphatidylinositol 3'-kinase pathway is a dominant growth factor-activated cell survival pathway in LNCaP human prostate carcinoma cells. J Lin RM Adam E Santiestevan MR Freeman, Cancer Res 1999 59 12 2891 2897 10383151
139. Calcium/calmodulin-dependent kinase II plays an important role in prostate cancer cell survival. OW Rokhlin AF Taghiyev KU Bayer D Bumcrot VE Koteliansk RA Glover MB Cohen, Cancer Biol Ther 2007 6 5 732 742 10.4161/cbt.6.5.3975 17387273
140. Mechanism of the eukaryotic chaperonin: protein folding in the chamber of secrets. C Spiess AS Meyer S Reissmann J Frydman, Trends Cell Biol 2004 14 11 598 604 10.1016/j.tcb.2004.09.015 15519848
141. Midkine and pleiotrophin in neural development and cancer. K Kadomatsu T Muramatsu, Cancer Lett 2004 204 2 127 143 10.1016/S0304-3835(03)00450-6 15013213
142. Midkine is a NFkappaB-inducible gene that supports prostate cancer cell survival. Z You Y Dong X Kong LA Beckett R Gandour-Edwards J Melamed, BMC Med Genomics 2008 1 6 10.1186/1755-8794-1-6 18275606
143. Functional screening for proapoptotic genes by reverse transfection cell array technology. O Mannherz D Mertens M Hahn P Lichter, Genomics 2006 87 5 665 672 10.1016/j.ygeno.2005.12.009 16503394
144. The role of the hypoxia-inducible BH3-only proteins BNIP3 and BNIP3L in cancer. HR Mellor AL Harris, Cancer Metastasis Rev 2007 26 3-4 553 566 10.1007/s10555-007-9080-0 17805942
145. WIPI-1alpha (WIPI49), a member of the novel 7-bladed WIPI protein family, is aberrantly expressed in human cancer and is linked to starvation-induced autophagy. T Proikas-Cezanne S Waddell A Gaugel T Frickey A Lupas A Nordheim, Oncogene 2004 23 58 9314 9325 10.1038/sj.onc.1208331 15602573
146. NADE, a p75NTR-associated cell death executor, is involved in signal transduction mediated by the common neurotrophin receptor p75NTR. J Mukai T Hachiya S Shoji-Hoshino MT Kimura D Nadano P Suvanto T Hanaoka Y Li S Irie LA Greene, et al. J Biol Chem 2000 275 23 17566 17570 10.1074/jbc.C000140200 10764727
147. Molecular characterization of the loss of p75(NTR) expression in human prostate tumor cells. S Krygier D Djakiew, Mol Carcinog 2001 31 1 46 55 10.1002/mc.1038 11398197